Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline
Vas Narasimhan has been CEO at Novartis for just a little more than a year since his promotion from development chief. And in today’s investor meeting, after spinning off Alcon and putting the wheels in motion to do a makeover at the suffering generics wing Sandoz, the spotlight is being turned straight at his prized possession: the pipeline.
He has a lot to boast about. But let’s start with the “25-plus” potential blockbusters in the clinic, along with 10-plus launches by 2021.
Many of these drugs are no stranger to the center ring, but there are some new additions to the lineup.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,600+ biopharma pros reading Endpoints daily — and it's free.